(VIANEWS) – Shares of MEDINCELL (CAC 40: MEDCL.PA) fell 9.24% to €7.27 at 11:05 EST on Friday, after three consecutive sessions in a row of losses. CAC 40 is jumping 0.87% to €7,446.30, following the last session’s upward trend. This seems, up until now, a somewhat positive trend trading session today.
MEDINCELL’s last close was €8.03, 23.52% below its 52-week high of €10.50.
About MEDINCELL
MedinCell S.A. develops various therapeutic solutions in France. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. The company's products in development include mdc-IRM, a risperidone extended-release injectable suspension completed Phase III trial for use in the treatment of schizophrenia; mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain & inflammation; and mdc-TJK, a subcutaneous injection in Phase III trials for use in the treatment of schizophrenia. Its product candidates in preclinical trials, such as mdc-ANG, an antipsychotic product for use in the treatment of schizophrenia; mdc-TTG for Covid-19 and its variants; mdc-GRT for use in organ transplant; mdc-WWM for contraception; mdc-STM for use in malaria; mdc-KPT for use in acute pain for pets; and mdc-IRM for use in neuroscience. The company was incorporated in 2003 and is based in Jacou, France.
Earnings Per Share
As for profitability, MEDINCELL has a trailing twelve months EPS of €-0.97.
Moving Average
MEDINCELL’s worth is way below its 50-day moving average of €8.98 and higher than its 200-day moving average of €6.88.
Yearly Top and Bottom Value
MEDINCELL’s stock is valued at €7.27 at 11:05 EST, way under its 52-week high of €10.50 and way above its 52-week low of €4.73.
More news about MEDINCELL (MEDCL.PA).
